Business
Investor Presentation
Investor Presentation.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n\n \n \n \nREACH: non-regulatory announcement*\n30 August 2023\nProteome Sciences plc\n(\"Proteome Sciences\" or the \"Company\")\n \nInvestor Presentation\nProteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on 19th Sep 2023 at 10:00am BST.\n \nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.\n \nInvestors can sign up to Investor Meet Company for free and add to meet Proteome Sciences plc via:\n \nhttps://www.investormeetcompany.com/proteome-sciences-plc/register-investor\n \nInvestors who already follow Proteome Sciences plc on the Investor Meet Company platform will automatically be invited.\n \n\n\n\nFor further information please contact:\n \nProteome Sciences plc\n\n\n\n\nDr. Mariola Soehngen, Chief Executive Officer\nDr. Ian Pike, Chief Scientific Officer\n\n\nTel: +44 (0)20 7043 2116\n\n\n \n\n\n\n\nRichard Dennis, Chief Commercial Officer\nAbdelghani Omari, Chief Financial Officer\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nAllenby Capital Limited (Nominated Adviser & Broker) \n\n\n \n\n\n\n\nJohn Depasquale / Jeremy Porter (Corporate Finance)\nTony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)\n\n\nTel: +44 (0) 20 3328 5656\n \n\n\n \n\n\n\n\n\n\n\n\nAbout Proteome Sciences plc. (www.proteomics.com)\n \nProteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarke...